EnglishGermanChinese (Simplified)FrenchJapanese

SYNTap™ Biomarker Test

This test identifies misfolded Synuclein, a biomarker driving Lewy Body Dementia (LBD or DLB), Parkinson’s Disease (PD), and other dementias, decades before symptoms. Why is this crucial? Imagine SEALs in night ops! To uncover evil’s lair, they must first equip themselves with infrared goggles. 🔍👁

What's the SYNTap Test?

Currently, the SYNTap test utilizes cerebral spinal fluid (CSF). We’re actively developing a blood test version. This biomarker test helps doctors diagnose certain cognitive and motor disorders. Accurate diagnosis guides proper drug treatment.

Four reasons to take the test:

I. Diagnosing Lewy Body Dementia (LBD):

LBD is a recently discovered brain disease, which sadly until now has only been definitively diagnosed after a patient has passed. So this is a game-changing test to diagnose LBD EARLY – before symptoms appear! 

Who should take this test?

  1. People who show both cognitive and motor symptoms.
  2. People at risk from genetics or family history and showing signs that their doctors believe might represent the early stages of the disease. 

lewy body dementia test

II. Diagnosing Parkinson’s:

SYNTap-CSF is a definitive test to help doctors diagnose Parkinson’s disease. It provides a precise method to detect Synuclein, a biomarker driving PD’s progression.

Who should take this test?

  1. People who show early signs of a motor disorder want to know with certainty whether they have progressive Parkinson’s disease.
  2. People at risk of Parkinson’s due to family history, genetic, previous head trauma, and what their doctors believe might represent early stages of Parkinson’s. 

parkinson's test

III. Differentiating Alzheimer’s vs. LBD in early stages

Patients showing early Alzheimer’s-like symptoms are often placed in a fuzzy gray zone of precarious uncertainty. 

“Do I have Alzheimer’s or Lewy Body Dementia, or something else?” 

This medical quagmire causes patients and their loved ones emotional, financial, and physical stress.

Did you know on average, someone suspecting Alzheimer’s endures 6 to 18-months of various tests costing about $45,000. And a lot of sleepless nights.

Who should take this test?

    1. People who show early signs of Alzheimer’s want to know with certainty of an Alzheimer’s diagnosis.
    2. People at risk of Alzheimer’s due to family history, genetics, and what their doctors believe might represent the early stages of Alzheimer’s. 

Alzheimer's test

The SYNTap Test helps physicians accurately identify whether the patient has Alzheimer’s or Lewy Body Dementia (LBD) when cognitive symptoms first appear. Before this test, patients endure prolonged, complicated procedures for differential diagnosis.

The diagnostic journey, in and of itself, is extremely costly emotionally and financially.

What do SYNTap Test results mean?

Positive SYNTap Test 

This means misfolded Synuclein aggregates are detected in the sample. Therefore, it accurately predicts the presence of Lewy Bodies. A positive SYNTap Test result indicates either a diagnosis of LBD, PD, or a mixed AD/LBD pathology. 

Negative SYNTap Test

A negative SYNTap Test rules out misfolded Synuclein as the cause, eliminating the likelihood of PD or LBD. As a result, physicians can focus on identifying other causes and prescribing proper treatments to manage symptoms.

A negative test rules out LBD or PD and triggers a better informed diagnostic protocol for Alzheimer’s.

It’s worth noting that people with symptoms can get a negative SYNTap Test result. This is because many brain diseases share similar symptoms as PD or LBD.

IV. Determining proper treatment for LATE STAGE Alzheimer’s patients

This test guides doctors to prescribe proper drug treatments on late-stage Alzheimer’s patients. Here is how:  

  1. Advanced Alzheimer’s patients often develop Parkinson’s-like motor symptoms years after the initial diagnosis. If/when the test shows Synuclein positive, the patient is likely to respond well to Synuclein-targeted medications.
  2. Research shows about 60% of Alzheimer’s patients have misfolded Synuclein in the late stages. By knowing the presence of Synuclein, doctors can treat advanced Alzheimer’s patients with appropriate Synuclein-targeted drugs.

TEST DIFFERENTIATING ALZ VS. LBD

Conversely, if the test comes back negative, Synuclein-targeted drugs may harm the patient. 

Accurate identification of the biomarker empowers treatment confidence, avoiding harmful drug mistreatment. 

Accurate diagnosis of Alzheimer’s vs. LBD is critical since both conditions show similar symptoms in the early stages.

Misdiagnosing Alzheimer’s vs. LBD can harm patients due the different drugs used to treat them. For example, drugs that work for Alzheimer’s patients can harm LBD patients, and vice versa. 

Alzheimer's Drug Development Funds Hero Image

Accurate diagnosis of Alzheimer’s vs. LBD is critical since both conditions show similar symptoms in the early stages.

Misdiagnosing Alzheimer’s vs. LBD can harm patients due the different drugs used to treat them. For example, drugs that work for Alzheimer’s patients can harm LBD patients, and vice versa. 

GET EARLY DETECTION TESTING!

Complete this short form to receive notifications on early testing availability for Alzheimer’s, Parkinson’s, and Lewy Body Dementia.

🔬Early detection empowers preventive care. Join us in the race to cures! 💪❤️

amprion logo quote solid blue
Do good by doing well, do well by doing good.
Scroll to Top
Share on facebook
Share on twitter
Share on linkedin